Remove 2014 Remove Healthcare Remove Safety
article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018. It also raises healthcare costs for public and private insurers alike. In my opinion, PhRMA has zero credibility.

Pharma 255
article thumbnail

Norstella, Citeline merge to create $5bn pharma tech firm

pharmaphorum

It has now joined Norstella’s four group companies – pharma intelligence unit Evaluate, market access specialist MMIT, healthcare data analytics software provider Panalgo and market access consultancy The Dedham Group – which were combined under the Norstella banner in May.

Pharma 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.” About the author.

article thumbnail

Psychedelic research: evaluating the fast-evolving regulatory roadmap

European Pharmaceutical Review

Despite the tidal wave of renewed interest in psychedelic therapies, there is still much to be learned about them, including their precise mechanisms of action, their long- and short-term safety profiles, the durability of their effect, and their adverse effects—which can be severe. Medicines and Healthcare products Regulatory Agency.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

The FDA’s role in the regulation of botanical drug products includes an assessment of their safety and efficiency 5 but insufficient evidence for efficacy is one of the most common reasons why new drug candidates fail to reach this step. 6 Thus, it is critical to ensure the consistency of therapeutic effect across batches (see box).

Marketing 103
article thumbnail

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part i)

pharmaphorum

The present moment within and without healthcare, biotech, and pharma is a difficult and pivotal time in history, a time in which such issues need must be addressed. The keynote address of the event entire came from Stella Kyriakides, commissioner for health and food safety at the European Commission. Her opener?

article thumbnail

Centerline Biomedical Raises $33 Million in Series B Financing

Legacy MEDSearch

Centerline), a private medical technology company, announced the closing of a $33 million Series B equity financing led by Cleveland Clinic with participation by GE Healthcare, RIK Enterprises, JobsOhio, Jumpstart Ventures and G2 Group Ventures. Founded in 2014, Centerline Biomedical is headquartered in Cleveland, Ohio.